Published • loading... • Updated
FDA drug center head expected to leave after commissioner's exit, sources say
Hoeg helped drive vaccine and drug policy changes that drew legal and scientific pushback, while several other Makary appointees are also expected to leave.
- Acting FDA drug center head Tracey Beth Hoeg is expected to leave the agency, according to three people familiar with internal planning, days after Commissioner Marty Makary resigned.
- During her five-month tenure, Hoeg reduced the recommended childhood vaccination schedule from 17 to 11 shots and initiated safety reviews for infant RSV treatments while questioning COVID-19 vaccine labels for men ages 12 to 24.
- Following Makary's resignation on Tuesday, White House aide Chris Klomp is replacing appointees described as controversial, including chief of staff Jim Traficant, deputy chief of staff Samuel Doran, and associate director Sanjula Jain-Nagpal.
- "HHS and FDA do not comment on personnel matters," HHS spokeswoman Emily Hilliard said, as the agency has experienced five leadership changes in 15 months.
- The White House has exerted increased control over the department recently as polls suggest vaccine policy changes could cost Republicans control of Congress in November's midterm elections.
Insights by Ground AI
8 Articles
8 Articles
FDA drug center head expected to leave after commissioner's exit, sources say
The acting head of the U.S. Food and Drug Administration's drug center, Tracey Beth Hoeg, is expected to leave the agency just days after Commissioner Marty Makary resigned, according to three people familiar with internal planning.
·United Kingdom
Read Full ArticleCoverage Details
Total News Sources8
Leaning Left0Leaning Right3Center5Last UpdatedBias Distribution63% Center
Bias Distribution
- 63% of the sources are Center
63% Center
C 63%
R 37%
Factuality
To view factuality data please Upgrade to Premium
